BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a collaboration in early August 2026 that includes BeOne funding a global Phase 3 trial for Revolution Medicines' RAS(ON) inhibitors. The deal combines BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors and grants BeOne exclusive development and commercialization rights in select Asian markets. This arrangement offloads near-term late-stage costs for Revolution Medicines, which reported a net loss of US$644.37 million for the second quarter of 2026 and US$1,098.19 million over six months. The core catalyst remains regulatory progress and eventual commercialization of daraxonrasib, with ongoing large-scale trial execution and spending still posing significant risk.
Revolution Medicines IncBeOne funding Phase 3 trial offloads late-stage costs for Revolution Medicines.
BeOne Medicines AGBeOne gains exclusive rights to RAS(ON) inhibitors in select Asian markets, expanding its oncology pipeline.
